We conducted a national retrospective survey on hospital practitioners to evaluate the magnitude of erythropoietin (EPO) or granulocyte colony-stimulating factor (G-CSF) prescriptions in patients treated for chronic hepatitis C. Four hundred seventy-one questionnaires were sent, and 274 practitioner
Re-evaluating the use of growth factors as adjuvant treatment of chronic hepatitis C
β Scribed by Howard J. Worman
- Publisher
- John Wiley and Sons
- Year
- 2007
- Tongue
- English
- Weight
- 54 KB
- Volume
- 46
- Category
- Article
- ISSN
- 0270-9139
No coin nor oath required. For personal study only.
π SIMILAR VOLUMES
## Background: Although experimental studies have demonstrated an important role of insulin-like growth factor i (igf-i) in hepatocarcinogenesis, the clinical data about igf-i in patients with hepatocellular carcinoma (hcc) are scarce and controversial. to the authors' knowledge, this is the first
## Abstract The TT virus (TTV) load was estimated in sera obtained from 237 patients with hepatitis C virus (HCV)βrelated chronic liver disease including 42 patients with hepatocellular carcinoma (HCC), by realβtime detection PCR using primers and a probe derived from the wellβconserved untranslate